Predicting Long-Term Remission in Ulcerative Colitis Patients on Vedolizumab
Author Information
Author(s): Chaemsupaphan Thanaboon, Pudipeddi Aviv, Lin Huiyu, Paramsothy Sudarshan, Kariyawasam Viraj, Kermeen Melissa, Leong Rupert W
Primary Institution: Concord Repatriation General Hospital, Sydney, New South Wales, Australia
Hypothesis
Can a scoring system be developed to predict 2-year clinical remission in ulcerative colitis patients treated with vedolizumab?
Conclusion
The study developed a scoring system that effectively predicts ongoing clinical remission in ulcerative colitis patients on vedolizumab.
Supporting Evidence
- 48 out of 62 patients maintained clinical remission over two years.
- The VIEWS score identified 2-year clinical remission with a sensitivity of 88.4% and specificity of 63.6%.
- Predictive factors included female sex, no previous anti-TNF exposure, and histological remission.
Takeaway
Doctors can use a new score to help figure out which ulcerative colitis patients will stay healthy on their medicine for a long time.
Methodology
Logistic regression was performed on prospectively recruited ulcerative colitis subjects to identify predictive factors for 2-year clinical remission.
Potential Biases
Potential bias due to the specific inclusion criteria of the study.
Limitations
The sample size was relatively small, which may affect generalizability.
Participant Demographics
The derivation cohort comprised 62 UC subjects (42% females, mean age 43.4 years).
Statistical Information
P-Value
0.03
Confidence Interval
95% CI, 0.81-0.98
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website